Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
Results filtered:Study status: Open Closed for Enrollment
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
The purpose of this study is to evaluate the effectiveness of CYP-001 and CS vs placebo and CS in adults with HR-aGvHD based on Overall Response Rate (ORR) at Day 28.